美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

新橋生物

1.59

-0.1000-5.92%

盤後：1.620.0300+1.89%19:51 EDT

成交量：25.28萬

成交額：40.72萬

市值：1.84億

市盈率：-2.41

高：1.71

開：1.70

低：1.58

收：1.69

52周最高：6.79

52周最低：1.46

股本：1.16億

流通股本：6,456.36萬

量比：1.58

換手率：0.39%

股息：- -

股息率：- -

每股收益(TTM):-0.6591

每股收益(LYR):-0.9225

淨資產收益率：-59.10%

總資產收益率：-34.98%

市淨率：0.92

市盈率(LYR):-1.72

資料載入中...

總覽公司新聞公告

新橋生物任命Martin Dewhurst為獨立董事

新橋生物公布2026年上半年財務業績，展示管線進展與戰略執行亮點

新橋生物發布2026年上半年財務業績，彰顯管線動能與戰略執行力

新橋生物將於2026年8月20日（周四）披露2026年上半年財務業績並發布公司最新動態

新橋生物任命Srishti Gupta博士為首席執行官

BUZZ——美國股市動態-安科科技、Dynatrace、Corvex

新橋生物Givastomig獲美國FDA快速通道認定，用於HER2陰性轉移性胃癌一線治療

市場快訊——美股行情動態-高通、Robinhood、Mobileye

熱門話題-NovaBridge股價上漲，因其胃癌聯合用藥獲FDA快速通道資格

新橋生物旗下Givastomig的註冊性三期臨床試驗最早有望於2026年第四季度啓動

新橋生物Givastomig獲FDA快速通道資格，用於一線治療HER2陰性轉移性胃癌

新橋生物：預計最早於2026年第四季度啓動註冊性三期聯合試驗

新橋生物：FDA確認Givastomig有望符合加速審批資格

新橋生物計劃於2026年第四季度啓動以客觀緩解率為主要終點的註冊性三期聯合試驗

新橋生物宣佈與FDA就胃腺癌藥物Givastomig加速審批路徑達成建設性B類會議

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/NBP/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NBP\",,,,,undefined,":{"symbol":"NBP","market":"US","secType":"STK","nameCN":"新橋生物","latestPrice":1.59,"timestamp":1789156800000,"preClose":1.69,"halted":0,"volume":252833,"hourTrading":{"tag":"盘后","latestPrice":1.62,"preClose":1.59,"latestTime":"19:51 EDT","volume":216,"amount":349.42,"timestamp":1789170664750,"change":0.03,"changeRate":0.018868,"amplitude":0.018868},"delay":0,"changeRate":-0.059171597633136015,"floatShares":64563600,"shares":115999216,"eps":-0.6591,"marketStatus":"休市中","change":-0.1,"latestTime":"09-11 16:00:00 EDT","open":1.7,"high":1.71,"low":1.58,"amount":407188.6083986,"amplitude":0.076923,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.6591,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"adrRate":2.3,"listingDate":1579237200000,"exchange":"NASDAQ","adjPreClose":1.69,"preHourTrading":{"tag":"盘前","latestPrice":1.6997,"preClose":1.69,"latestTime":"09:12 EDT","volume":1157,"amount":1945.8296416,"timestamp":1789132322472,"change":0.0097,"changeRate":0.00574,"amplitude":0.017751},"postHourTrading":{"tag":"盘后","latestPrice":1.62,"preClose":1.59,"latestTime":"19:51 EDT","volume":216,"amount":349.42,"timestamp":1789170664750,"change":0.03,"changeRate":0.018868,"amplitude":0.018868},"volumeRatio":1.575022456061781,"impliedVol":0.9503,"impliedVolPercentile":0.4424},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NBP\",,,,,undefined,":{"symbol":"NBP","floatShares":64563600,"roa":"-34.98%","roe":"-59.10%","lyrEps":-0.922468,"volumeRatio":1.575022456061781,"shares":115999216,"dividePrice":0,"high":1.71,"amplitude":0.076923,"preClose":1.69,"low":1.58,"week52Low":1.46,"pbRate":"0.92","week52High":6.79,"institutionHeld":0,"latestPrice":1.59,"eps":-0.6591,"divideRate":0,"volume":252833,"delay":0,"ttmEps":-0.6591,"open":1.7,"prevYearClose":3.98,"prevWeekClose":1.8,"prevMonthClose":1.82,"prevQuarterClose":1.95,"fiveDayClose":1.8,"twentyDayClose":1.9,"sixtyDayClose":1.51},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NBP\",params:#limit:5,,,undefined,":[{"date":"2026-08-20","symbol":"NBP","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787212800000,"name":null,"time":"盤前","dateTimestamp":1787198400000,"actualEps":null},{"market":"US","date":"2026-04-07","symbol":"NBP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1775534400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-08-20","symbol":"NBP","fiscalQuarterEnding":"2025/06","expectedEps":-0.1,"name":null,"time":"盤前","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"pre","actualEps":-0.07},{"market":"US","date":"2025-05-15","symbol":"NBP","fiscalQuarterEnding":"2025/03","expectedEps":-0.07,"name":null,"time":"盤前","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.04},{"market":"US","date":"2025-04-03","symbol":"NBP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1743652800000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NBP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":4,"updateTime":1759550400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NBP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NBP","date":"2026-09-11","current":-2.412381,"percent":1,"low":-20.276437,"twenty":-14.425612,"median":-3.53465,"eighty":-2.290977,"high":-1.667648,"avg":-8.236858,"sd":6.09552,"marketCap":196038675},"quantilePoints":[{"date":"2025-10-31","current":-13.114792,"twenty":-13.114792,"median":-13.114792,"eighty":-13.114792,"marketCap":524460541},{"date":"2025-11-07","current":-12.077138,"twenty":-13.547148,"median":-12.71126,"eighty":-12.278904,"marketCap":482964762},{"date":"2025-11-14","current":-12.019491,"twenty":-13.114792,"median":-12.278904,"eighty":-12.077138,"marketCap":480659441},{"date":"2025-11-21","current":-12.077138,"twenty":-13.085968,"median":-12.293316,"eighty":-12.077138,"marketCap":482964762},{"date":"2025-11-28","current":-11.068308,"twenty":-13.06291,"median":-12.192433,"eighty":-11.881137,"marketCap":442621643},{"date":"2025-12-05","current":-11.500664,"twenty":-12.688201,"median":-12.077138,"eighty":-11.212426,"marketCap":459911551},{"date":"2025-12-12","current":-11.298898,"twenty":-12.411494,"median":-12.033903,"eighty":-11.287368,"marketCap":451842927},{"date":"2025-12-19","current":-17.342266,"twenty":-12.688201,"median":-12.048315,"eighty":-11.460311,"marketCap":456552482},{"date":"2025-12-26","current":-20.276437,"twenty":-13.287734,"median":-12.077138,"eighty":-11.500664,"marketCap":533797473},{"date":"2026-01-02","current":-17.429853,"twenty":-17.342266,"median":-12.163609,"eighty":-11.512194,"marketCap":458858303},{"date":"2026-01-09","current":-16.597774,"twenty":-17.482405,"median":-12.235668,"eighty":-11.541017,"marketCap":436953007},{"date":"2026-01-16","current":-16.028458,"twenty":-17.394818,"median":-12.365376,"eighty":-11.569841,"marketCap":421965173},{"date":"2026-01-23","current":-17.03571,"twenty":-17.342266,"median":-13.057145,"eighty":-11.587135,"marketCap":448482110},{"date":"2026-01-30","current":-16.116045,"twenty":-17.3773,"median":-13.33097,"eighty":-11.615959,"marketCap":424270994},{"date":"2026-02-06","current":-14.583269,"twenty":-17.342266,"median":-14.495682,"eighty":-11.742783,"marketCap":383919133},{"date":"2026-02-13","current":-14.189126,"twenty":-17.307231,"median":-14.71465,"eighty":-11.823489,"marketCap":373542940},{"date":"2026-02-20","current":-14.539475,"twenty":-17.167091,"median":-14.517578,"eighty":-11.961843,"marketCap":382766222},{"date":"2026-02-27","current":-14.364301,"twenty":-17.03571,"median":-14.408094,"eighty":-12.019491,"marketCap":378154581},{"date":"2026-03-06","current":-15.94087,"twenty":-17.03571,"median":-14.386197,"eighty":-12.048315,"marketCap":419659352},{"date":"2026-03-13","current":-12.875318,"twenty":-16.991917,"median":-14.364301,"eighty":-12.077138,"marketCap":338955631},{"date":"2026-03-20","current":-11.780478,"twenty":-16.948123,"median":-14.316021,"eighty":-12.077138,"marketCap":310132873},{"date":"2026-03-27","current":-11.167368,"twenty":-16.597774,"median":-14.189126,"eighty":-11.788901,"marketCap":293992129},{"date":"2026-04-02","current":-10.773226,"twenty":-16.597774,"median":-14.101539,"eighty":-11.587135,"marketCap":283615936},{"date":"2026-04-10","current":-3.171352,"twenty":-16.387565,"median":-14.057746,"eighty":-11.527134,"marketCap":280157205},{"date":"2026-04-17","current":-3.495376,"twenty":-16.299978,"median":-13.61981,"eighty":-11.287368,"marketCap":308781505},{"date":"2026-04-24","current":-3.23355,"twenty":-16.221149,"median":-13.10038,"eighty":-11.118286,"marketCap":285651804},{"date":"2026-05-01","current":-3.23355,"twenty":-16.203632,"median":-12.875318,"eighty":-11.061844,"marketCap":285651804},{"date":"2026-05-08","current":-2.906268,"twenty":-16.133562,"median":-12.604261,"eighty":-10.634902,"marketCap":256739678},{"date":"2026-05-15","current":-2.513529,"twenty":-16.045975,"median":-12.365376,"eighty":-3.526795,"marketCap":222045127},{"date":"2026-05-22","current":-2.330251,"twenty":-15.993423,"median":-12.293316,"eighty":-3.374936,"marketCap":205854337},{"date":"2026-05-29","current":-2.448072,"twenty":-15.958388,"median":-12.192433,"eighty":-3.235384,"marketCap":216262702},{"date":"2026-06-05","current":-2.356433,"twenty":-15.651833,"median":-12.134786,"eighty":-3.190946,"marketCap":208167307},{"date":"2026-06-12","current":-1.92442,"twenty":-15.393451,"median":-12.062727,"eighty":-3.136675,"marketCap":170003300},{"date":"2026-06-18","current":-2.055333,"twenty":-15.340898,"median":-11.990667,"eighty":-3.100019,"marketCap":181568151},{"date":"2026-06-26","current":-2.094607,"twenty":-15.292725,"median":-11.780478,"eighty":-2.890558,"marketCap":185037606},{"date":"2026-07-02","current":-2.605168,"twenty":-15.231414,"median":-11.587135,"eighty":-2.686334,"marketCap":230140522},{"date":"2026-07-10","current":-2.434981,"twenty":-15.178862,"median":-11.559911,"eighty":-2.610404,"marketCap":215106217},{"date":"2026-07-17","current":-2.343342,"twenty":-15.091275,"median":-11.517717,"eighty":-2.516147,"marketCap":207010822},{"date":"2026-07-24","current":-2.317159,"twenty":-15.012446,"median":-11.399781,"eighty":-2.437599,"marketCap":204697852},{"date":"2026-07-31","current":-2.146972,"twenty":-14.977411,"median":-11.226206,"eighty":-2.42189,"marketCap":189663546},{"date":"2026-08-07","current":-2.22552,"twenty":-14.977411,"median":-11.123574,"eighty":-2.356433,"marketCap":196602456},{"date":"2026-08-14","current":-2.487346,"twenty":-14.84603,"median":-11.068308,"eighty":-2.356433,"marketCap":219732157},{"date":"2026-08-21","current":-1.87904,"twenty":-14.583269,"median":-11.035987,"eighty":-2.356433,"marketCap":220888642},{"date":"2026-08-28","current":-1.865003,"twenty":-14.539475,"median":-10.707535,"eighty":-2.330251,"marketCap":219238518},{"date":"2026-09-04","current":-1.776193,"twenty":-14.495682,"median":-10.598051,"eighty":-2.317159,"marketCap":208798588},{"date":"2026-09-11","current":-1.667648,"twenty":-14.425612,"median":-3.53465,"eighty":-2.290977,"marketCap":196038675}],"updateTime":1789255070388},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NBP\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665788583","title":"新橋生物任命Martin Dewhurst為獨立董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2665788583","media":"美通社","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665788583?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 19:05","pubTimestamp":1788865500,"startTime":"0","endTime":"0","summary":"上海2026年9月8日 /美通社/ -- 9月8日，新桥生物，一家专注于识别差异化创新，并采用严谨的开发、融资与合作策略以创造价值的全球生物技术公司，今日宣布，任命Martin Dewhurst先生为董事会独立董事，同时担任审计委员会及薪酬委员会成员，即时生效。\" 对于加入新桥生物董事会，Martin Dewhurst先生表示，\"很荣幸在新桥生物发展的重要阶段加入董事会。\" 本次任命是在独立董事刘欣离任后作出的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5042230_ZH42230_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5042230_ZH42230_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660284309","title":"新橋生物公布2026年上半年財務業績，展示管線進展與戰略執行亮點","url":"https://stock-news.laohu8.com/highlight/detail?id=2660284309","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660284309?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 19:11","pubTimestamp":1787224260,"startTime":"0","endTime":"0","summary":"2026年上半年，公司持续推进战略重点事项，推动核心管线取得关键临床进展，并强化了领导力、治理能力与资本配置。\" 新桥生物董事会主席傅唯表示。管线概览及近期潜在里程碑 新桥生物两大核心管线体现了公司战略核心的互补能力。2026年上半年财务业绩 现金状况 截至2026年6月30日，公司现金、现金等价物、短期投资及以公允价值计价的股权投资为2.159亿美元。研发费用 截至2026年6月30日止的六个月，研究与开发","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5030485_ZH30485_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5030485_ZH30485_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165817918","title":"新橋生物發布2026年上半年財務業績，彰顯管線動能與戰略執行力","url":"https://stock-news.laohu8.com/highlight/detail?id=1165817918","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165817918?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 19:01","pubTimestamp":1787223693,"startTime":"0","endTime":"0","summary":"新桥生物（NovaBridge Biosciences）今日披露了截至2026年6月30日的上半年财务报告，同时对外强调了其研发管线的持续推进态势，以及公司在战略层面所展现出的高效执行力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110507548","title":"新橋生物將於2026年8月20日（周四）披露2026年上半年財務業績並發布公司最新動態","url":"https://stock-news.laohu8.com/highlight/detail?id=1110507548","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110507548?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 05:01","pubTimestamp":1786654869,"startTime":"0","endTime":"0","summary":"新桥生物（NovaBridge Biosciences）计划于2026年8月20日（星期四）公布其2026年上半年财务报告，届时也将同步更新公司业务进展与战略部署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647530512","title":"新橋生物任命Srishti Gupta博士為首席執行官","url":"https://stock-news.laohu8.com/highlight/detail?id=2647530512","media":"美通社","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647530512?lang=zh_tw&edition=fundamental","pubTime":"2026-06-29 20:08","pubTimestamp":1782734880,"startTime":"0","endTime":"0","summary":"新桥生物董事会主席傅唯表示， \"Srishti兼具医生和首席执行官的双重视角，使她成为领导新桥生物的绝佳人选。\" 新桥生物首席执行官Srishti Gupta博士表示，\"前沿科学的创新速度，已超越行业将其传化为患者可及疗法的能力，而新桥生物正是为了弥合这一差距而创立。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/4994052_ZH94052_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4994052_ZH94052_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643766548","title":"BUZZ——美國股市動態-安科科技、Dynatrace、Corvex","url":"https://stock-news.laohu8.com/highlight/detail?id=2643766548","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643766548?lang=zh_tw&edition=fundamental","pubTime":"2026-06-16 23:39","pubTimestamp":1781624358,"startTime":"0","endTime":"0","summary":".N美国东部时间11:30，道琼斯工业平均指数 .DJI 上涨0.74%，报52,052.39点。标普500指数 .SPX 下跌0.21%，报7,538.57点；纳斯达克综合指数 .IXIC 下跌0.42%，报26,571.37点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nL4S42O1KM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","AMKR","HOOG","LION","LITE","MBOT","QCMU","LITX","HUN","NEO","SUGP","ROBN","SPCX","HUBB","AMPH","EWTX","MOVE","NCLH","XOMO","RCL","MBLY","QCOM","COHR","MOGU","XOM","WBX","CCL.UK","BAND","GDC","BAC","MAC","GIL","SPAL","OLN","CCL","DT","HIMS","NBP","ALVO","INTC","HSPT","MRNA","PLAY","WDC","YUM","LUV","HOOD","TGE","CIIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643635257","title":"新橋生物Givastomig獲美國FDA快速通道認定，用於HER2陰性轉移性胃癌一線治療","url":"https://stock-news.laohu8.com/highlight/detail?id=2643635257","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643635257?lang=zh_tw&edition=fundamental","pubTime":"2026-06-16 21:12","pubTimestamp":1781615520,"startTime":"0","endTime":"0","summary":"FDA快速通道认定，旨在加速针对存在未被满足医疗需求的严重疾病疗法的研发与审评。新桥生物首席医学官Phillip Dennis博士表示，\"获得快速通道认定，对Givastomig以及一线HER2阴性转移性胃癌患者而言，是意义重大的一步。Ib期结果显示，Givastomig联合免疫化疗具有稳健的疗效和良好的总体耐受性。Givastomig 目前处于开发阶段，有望用于治疗胃癌及其他CLDN18.2阳性的胃肠道恶性肿瘤。Givastomig 由新桥生物与ABL Bio公司通过一项全球合作共同开发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/4984809_ZH84809_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4984809_ZH84809_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4139","BK4585","BK4588","LABU","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643710751","title":"市場快訊——美股行情動態-高通、Robinhood、Mobileye","url":"https://stock-news.laohu8.com/highlight/detail?id=2643710751","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643710751?lang=zh_tw&edition=fundamental","pubTime":"2026-06-16 19:34","pubTimestamp":1781609681,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nL4T42O0ZU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","MAC","GB00BDT5M118.USD","BK4605","BK4554","BK4124","BK4139","SG9999015952.SGD","MBLY","BK4080","BK4231","LU1823568750.SGD","LU0942090050.USD","BK4581","SG9999015978.USD","LU1861558580.USD","BK4547","HIMY","LU0868494708.USD","BK4598","BK4127","LU2247934214.USD","LU1974910355.USD","IE00BVYPNP33.GBP","LU1069344957.HKD","BK4141","LU2106854487.HKD","BK4098","ALVO","LU0054578231.USD","LU1084165304.USD","LU1917777945.USD","BK4551","HOOG","HOOD","BK4612","HIYY","HOII","LU1046421795.USD","HIMS","HOOZ","SG9999015945.SGD","IE00BSNM7G36.USD","LU1261432733.SGD","LU0081259029.USD","BK4573","LU0079474960.USD","BK4585","LU2065169927.USD","LU1119994496.HKD","LU1244550221.USD","LU1244550577.SGD","IE00BGHQDM52.EUR","LU1244550494.USD","LU2023250504.SGD","HUN","SG9999002224.SGD","BK4515","BK4539","HMYY","LU1861559042.SGD","BK4604","BK4512","SG9999002232.USD","BK4588","LU2065171402.SGD","BK4575","BK4527","NBP","BK4579","HIMZ","LU2065170008.USD","BK4532","HODU","LU1035775433.USD","BK4157","LU1496350502.SGD","LU0868494617.USD","SG9999001424.SGD","BK4534","QCMD","SG9999015986.USD","HOYY","BK4561","HOOY","LU1066051811.HKD","ROBN","LU1066053197.SGD","QCML","HOOX","LU0061475181.USD","HOOW","IE00BVYPNQ40.USD","LU2065171311.SGD","QCMU","HOOI","LU1066051498.USD","QCOM","LU1066051225.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643585751","title":"熱門話題-NovaBridge股價上漲，因其胃癌聯合用藥獲FDA快速通道資格","url":"https://stock-news.laohu8.com/highlight/detail?id=2643585751","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643585751?lang=zh_tw&edition=fundamental","pubTime":"2026-06-16 19:17","pubTimestamp":1781608657,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nL4T42O0YR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199400680","title":"新橋生物旗下Givastomig的註冊性三期臨床試驗最早有望於2026年第四季度啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=1199400680","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199400680?lang=zh_tw&edition=fundamental","pubTime":"2026-06-16 19:01","pubTimestamp":1781607678,"startTime":"0","endTime":"0","summary":"新桥生物（NovaBridge Biosciences）宣布，其核心候选药物Givastomig的注册性三期临床试验，预计最早将于2026年第四季度开始。这一关键性试验的启动，标志着该药物在特定适应症研发进程中迈入决定性阶段，为后续的监管申报和潜在商业化铺平道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148595922","title":"新橋生物Givastomig獲FDA快速通道資格，用於一線治療HER2陰性轉移性胃癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1148595922","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148595922?lang=zh_tw&edition=fundamental","pubTime":"2026-06-16 19:00","pubTimestamp":1781607647,"startTime":"0","endTime":"0","summary":"新桥生物宣布，其研发的Givastomig已获得美国食品药品监督管理局（FDA）授予的快速通道资格，该资格针对的适应症为一线治疗HER2阴性转移性胃癌。此项认定有望加速该药物的研发与审评进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164386189","title":"新橋生物：預計最早於2026年第四季度啓動註冊性三期聯合試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1164386189","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164386189?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 20:42","pubTimestamp":1773664949,"startTime":"0","endTime":"0","summary":"新桥生物宣布，公司计划最早在2026年第四季度开展一项注册性三期联合临床试验。这一关键进展标志着其在创新疗法开发道路上迈出重要一步，为后续商业化布局奠定基础。通过将不同治疗机制相结合，该试验旨在探索更优临床效果，为患者提供突破性治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120501405","title":"新橋生物：FDA確認Givastomig有望符合加速審批資格","url":"https://stock-news.laohu8.com/highlight/detail?id=1120501405","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120501405?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 20:39","pubTimestamp":1773664740,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式确认，新桥生物（NovaBridge Biosciences）旗下在研药物Givastomig具备潜在资格，有望通过加速审批通道推进上市进程。\n这一进展意味着，若后续临床试验数据积极，Givastomig或可基于替代终点提前获批，从而缩短其进入市场的时间。加速审批路径通常适用于针对严重疾病、且现有治疗选择有限的创新疗法。\n新桥生物表示，将继续与FDA保持密切沟通，积极推进Givastomig的临床开发计划，以期早日为患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139570168","title":"新橋生物計劃於2026年第四季度啓動以客觀緩解率為主要終點的註冊性三期聯合試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1139570168","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139570168?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 19:03","pubTimestamp":1773658990,"startTime":"0","endTime":"0","summary":"新桥生物（NovaBridge Biosciences）宣布，公司将于2026年第四季度正式启动一项注册性三期联合疗法临床试验。该试验将采用客观缓解率（ORR）作为主要疗效终点，旨在评估创新疗法组合在目标患者群体中的治疗效果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106527073","title":"新橋生物宣佈與FDA就胃腺癌藥物Givastomig加速審批路徑達成建設性B類會議","url":"https://stock-news.laohu8.com/highlight/detail?id=1106527073","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106527073?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 19:02","pubTimestamp":1773658924,"startTime":"0","endTime":"0","summary":"新桥生物（NovaBridge Biosciences）近日披露，该公司与美国食品药品监督管理局（FDA）针对其在研药物Givastomig用于治疗胃腺癌的加速批准路径，成功举行了一场富有成效的B类会议。\n此次会议重点探讨了Givastomig通过加速审批通道上市的可能性，双方就后续临床开发策略及数据要求达成重要共识。该进展标志着Givastomig在胃腺癌治疗领域的商业化进程迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":15,"code":"91000000","status":"200"}]}}